Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.53 | N/A | +1.34% |
management commentary, guidance changes, and full analysis available with Pro.
| +1.34% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to shareholder value. However, no specific guidance was provided for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering value to shareholders.
Pfizer's earnings report showed a slight beat on EPS, which indicates some operational strength. However, the stock reacted negatively, declining by 1.29%. This may reflect investor concerns about the lack of revenue data and future guidance, leaving uncertainty about the company's growth trajectory.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PG&E CORP
Oct 29, 2012